search
Back to results

Efficacy of Pantoprazole in Patients Older Than 18 Years Who Have Symptoms of Non-erosive Reflux or Gastroesophageal Reflux Disease (BY1023/DE-004)

Primary Purpose

Gastroesophageal Reflux

Status
Completed
Phase
Phase 3
Locations
Germany
Study Type
Interventional
Intervention
Pantoprazole
Sponsored by
Nycomed
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Gastroesophageal Reflux focused on measuring GERD, Pantoprazole, NERD

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Main Inclusion Criteria: Written informed consent Inpatients (hospitalization during the entire study period is mandatory) Symptomatic (heartburn, acid regurgitation or dysphagia for at least 1 day since admission to the hospital) non-erosive reflux disease (NERD) or erosive gastroesophageal reflux disease (GERD, LA Grade A-D) Main Exclusion Criteria: Known Zollinger-Ellison syndrome or other gastric hypersecretory condition Previous acid-lowering surgery or other surgery of the esophagus and/or upper gastrointestinal tract (exception: polypectomy and cholecystectomy) On initial endoscopy, presence of obstructive esophageal strictures, Schatzki's ring, esophageal diverticula, esophageal varices, achalasia or Barrett's esophagus with known high-grade dysplasia or longer than 3 cm Acute peptic ulcer and/or ulcer complications Pyloric stenosis Known inflammatory bowel diseases

Sites / Locations

  • Nycomed Deutschland GmbH
  • Nycomed Deutschland GmbH
  • Nycomed Deutschland GmbH
  • Nycomed Deutschland GmbH
  • Nycomed Deutschland GmbH
  • Nycomed Deutschland GmbH
  • Nycomed Deutschland GmbH
  • Nycomed Deutschland GmbH
  • Nycomed Deutschland GmbH
  • Nycomed Deutschland GmbH
  • Nycomed Deutschland GmbH
  • Nycomed Deutschland GmbH
  • Nycomed Deutschland GmbH
  • Nycomed Deutschland GmbH
  • Nycomed Deutschland GmbH
  • Nycomed Deutschland GmbH
  • Nycomed Deutschland GmbH
  • Nycomed Deutschland GmbH
  • Nycomed Deutschland GmbH
  • Nycomed Deutschland GmbH
  • Nycomed Deutschland GmbH
  • Nycomed Deutschland GmbH
  • Nycomed Deutschland GmbH
  • Nycomed Deutschland GmbH
  • Nycomed Deutschland GmbH
  • Nycomed Deutschland GmbH
  • Nycomed Deutschland GmbH
  • Nycomed Deutschland GmbH
  • Nycomed Deutschland GmbH
  • Nycomed Deutschland GmbH
  • Nycomed Deutschland GmbH
  • Nycomed Deutschland GmbH
  • Nycomed Deutschland GmbH
  • Nycomed Deutschland GmbH
  • Nycomed Deutschland GmbH

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

1

2

Arm Description

Pantoprazole 20 mg

Pantoprazole 40 mg

Outcomes

Primary Outcome Measures

Symptom reduction from reflux disease related symptoms as measured by the questionnaire ReQuest™-GI (gastrointestinal) after 1 day of treatment

Secondary Outcome Measures

Symptom reduction from reflux disease related symptoms as measured by the questionnaire ReQuest™-GI (gastrointestinal) after 2 to 7 days of treatment
Symptom relief rates as measured by ReQuest™ after 7 days of treatment
Safety

Full Information

First Posted
May 15, 2006
Last Updated
May 4, 2012
Sponsor
Nycomed
search

1. Study Identification

Unique Protocol Identification Number
NCT00326027
Brief Title
Efficacy of Pantoprazole in Patients Older Than 18 Years Who Have Symptoms of Non-erosive Reflux or Gastroesophageal Reflux Disease (BY1023/DE-004)
Official Title
Profi-Study: Symptom Reduction in Hospitalized Patients Suffering From Symptomatic Non-erosive or Erosive Gastroesophageal Reflux Disease Treated With Pantoprazole 20 or 40 mg o.d. for 7 Days
Study Type
Interventional

2. Study Status

Record Verification Date
May 2012
Overall Recruitment Status
Completed
Study Start Date
October 2006 (undefined)
Primary Completion Date
July 2007 (Actual)
Study Completion Date
November 2007 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Nycomed

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The aim of the study is to evaluate the effect of pantoprazole on fast symptom reduction in hospitalized patients with NERD (non-erosive reflux disease) or GERD (gastroesophageal reflux disease, Los Angeles [LA] Grade A-D). During the study, the patients will complete a patient-orientated, self-assessed reflux questionnaire (ReQuest™). The study duration consists of a treatment period of 7 days ± 3 days. Pantoprazole (tablet) will be administered once daily in the morning to patients with NERD or GERD at one dose level for each indication. The study will provide further data on the safety and tolerability of pantoprazole.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gastroesophageal Reflux
Keywords
GERD, Pantoprazole, NERD

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
29 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Active Comparator
Arm Description
Pantoprazole 20 mg
Arm Title
2
Arm Type
Active Comparator
Arm Description
Pantoprazole 40 mg
Intervention Type
Drug
Intervention Name(s)
Pantoprazole
Intervention Description
Efficacy of Pantoprazole
Primary Outcome Measure Information:
Title
Symptom reduction from reflux disease related symptoms as measured by the questionnaire ReQuest™-GI (gastrointestinal) after 1 day of treatment
Time Frame
1 day
Secondary Outcome Measure Information:
Title
Symptom reduction from reflux disease related symptoms as measured by the questionnaire ReQuest™-GI (gastrointestinal) after 2 to 7 days of treatment
Time Frame
7 days
Title
Symptom relief rates as measured by ReQuest™ after 7 days of treatment
Time Frame
7 days
Title
Safety
Time Frame
7 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Main Inclusion Criteria: Written informed consent Inpatients (hospitalization during the entire study period is mandatory) Symptomatic (heartburn, acid regurgitation or dysphagia for at least 1 day since admission to the hospital) non-erosive reflux disease (NERD) or erosive gastroesophageal reflux disease (GERD, LA Grade A-D) Main Exclusion Criteria: Known Zollinger-Ellison syndrome or other gastric hypersecretory condition Previous acid-lowering surgery or other surgery of the esophagus and/or upper gastrointestinal tract (exception: polypectomy and cholecystectomy) On initial endoscopy, presence of obstructive esophageal strictures, Schatzki's ring, esophageal diverticula, esophageal varices, achalasia or Barrett's esophagus with known high-grade dysplasia or longer than 3 cm Acute peptic ulcer and/or ulcer complications Pyloric stenosis Known inflammatory bowel diseases
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Joachim Mössner, Prof.
Organizational Affiliation
Universitätsklinikum Leipzig, Leipzig, Germany
Official's Role
Principal Investigator
Facility Information:
Facility Name
Nycomed Deutschland GmbH
City
Augsburg
ZIP/Postal Code
86156
Country
Germany
Facility Name
Nycomed Deutschland GmbH
City
Berlin
ZIP/Postal Code
10117
Country
Germany
Facility Name
Nycomed Deutschland GmbH
City
Brandenburg
ZIP/Postal Code
14770
Country
Germany
Facility Name
Nycomed Deutschland GmbH
City
Erlangen
ZIP/Postal Code
91054
Country
Germany
Facility Name
Nycomed Deutschland GmbH
City
Frankfurt
ZIP/Postal Code
60488
Country
Germany
Facility Name
Nycomed Deutschland GmbH
City
Frankfurt
ZIP/Postal Code
60569
Country
Germany
Facility Name
Nycomed Deutschland GmbH
City
Gera
ZIP/Postal Code
07548
Country
Germany
Facility Name
Nycomed Deutschland GmbH
City
Greifswald
ZIP/Postal Code
17489
Country
Germany
Facility Name
Nycomed Deutschland GmbH
City
Göttingen
ZIP/Postal Code
37075
Country
Germany
Facility Name
Nycomed Deutschland GmbH
City
Halle (Saale)
ZIP/Postal Code
06110
Country
Germany
Facility Name
Nycomed Deutschland GmbH
City
Hamburg
ZIP/Postal Code
21075
Country
Germany
Facility Name
Nycomed Deutschland GmbH
City
Hamburg
ZIP/Postal Code
22457
Country
Germany
Facility Name
Nycomed Deutschland GmbH
City
Ingolstadt
ZIP/Postal Code
85049
Country
Germany
Facility Name
Nycomed Deutschland GmbH
City
Jena
ZIP/Postal Code
07747
Country
Germany
Facility Name
Nycomed Deutschland GmbH
City
Kassel
ZIP/Postal Code
34125
Country
Germany
Facility Name
Nycomed Deutschland GmbH
City
Kiel
ZIP/Postal Code
24105
Country
Germany
Facility Name
Nycomed Deutschland GmbH
City
Köln
ZIP/Postal Code
51067
Country
Germany
Facility Name
Nycomed Deutschland GmbH
City
Köln
ZIP/Postal Code
51109
Country
Germany
Facility Name
Nycomed Deutschland GmbH
City
Leipzig
ZIP/Postal Code
04103
Country
Germany
Facility Name
Nycomed Deutschland GmbH
City
Ludwigsburg
ZIP/Postal Code
71640
Country
Germany
Facility Name
Nycomed Deutschland GmbH
City
Ludwigshafen
ZIP/Postal Code
67063
Country
Germany
Facility Name
Nycomed Deutschland GmbH
City
Lübeck
ZIP/Postal Code
23538
Country
Germany
Facility Name
Nycomed Deutschland GmbH
City
Mainz
ZIP/Postal Code
55131
Country
Germany
Facility Name
Nycomed Deutschland GmbH
City
Marburg
ZIP/Postal Code
35043
Country
Germany
Facility Name
Nycomed Deutschland GmbH
City
Minden
ZIP/Postal Code
32427
Country
Germany
Facility Name
Nycomed Deutschland GmbH
City
München
ZIP/Postal Code
81377
Country
Germany
Facility Name
Nycomed Deutschland GmbH
City
Münster
ZIP/Postal Code
48149
Country
Germany
Facility Name
Nycomed Deutschland GmbH
City
Neubrandenburg
ZIP/Postal Code
17036
Country
Germany
Facility Name
Nycomed Deutschland GmbH
City
Offenbach
ZIP/Postal Code
63069
Country
Germany
Facility Name
Nycomed Deutschland GmbH
City
Oldenburg
ZIP/Postal Code
26133
Country
Germany
Facility Name
Nycomed Deutschland GmbH
City
Recklinghausen
ZIP/Postal Code
45655
Country
Germany
Facility Name
Nycomed Deutschland GmbH
City
Rostock
ZIP/Postal Code
18057
Country
Germany
Facility Name
Nycomed Deutschland GmbH
City
Stade
ZIP/Postal Code
21682
Country
Germany
Facility Name
Nycomed Deutschland GmbH
City
Weimar
ZIP/Postal Code
99425
Country
Germany
Facility Name
Nycomed Deutschland GmbH
City
Wiesbaden
ZIP/Postal Code
65189
Country
Germany

12. IPD Sharing Statement

Learn more about this trial

Efficacy of Pantoprazole in Patients Older Than 18 Years Who Have Symptoms of Non-erosive Reflux or Gastroesophageal Reflux Disease (BY1023/DE-004)

We'll reach out to this number within 24 hrs